THERAPY OF PATIENTS WITH CHRONIC PYODERMA BY DRY ACELLULAR STAPHYLOCOCCAL VACCINE

Presents the findings of clinical studies of the efficacy of a new dry acellular staphylococcal vaccine, manufactured by the Mechnikoff Cent ral Research Institute for Vaccines and Sera, used in combined therapy of patients with various forms of chronic pyoderma. The results of va ccinal therapy were assessed by the vaccine tolerance, time course of resolution of the clinical manifestations of the disease and the late results (up to 3 years) of the treatment as against therapy with the c ommercial staphylococcal vaccine (antiphagin) and the reference group. The new vaccine was well tolerated, its advantages in comparison with the commercial vaccine (antiphagin) and the traditional therapy were demonstrated. The vaccine manufactured by the Mechnikoff Institute is recommended for both combined therapy of patients with chronic pyoderm a and for the prevention of the condition recurrences.